390
Participants
Start Date
June 30, 2013
Primary Completion Date
July 31, 2014
Study Completion Date
November 30, 2014
Low dose of H5 VLP vaccine + Alhydrogel
Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
Med dose of H5 VLP vaccine + Alhydrogel
Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
High dose of H5 VLP vaccine + Alhydrogel
Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
Low dose of H5 VLP vaccine + GLA-SE
Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
High dose of H5 VLP vaccine + GLA-SE
Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
Placebo comparator: Placebo
Biological: Placebo 2 doses given 21 days apart of the placebo
INC Research, Toronto
MUHC Vaccine Study Center, Pierrefonds
Lead Sponsor
Collaborators (1)
Syneos Health
OTHER
McGill University Health Centre/Research Institute of the McGill University Health Centre
OTHER
Medicago
INDUSTRY